Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017 (2017), Article ID 9538920, 4 pages
https://doi.org/10.1155/2017/9538920
Case Report

Successful Long-Term Use of Eltrombopag in a Patient with Refractory Severe Thrombocytopenia Associated with Chronic Lymphocytic Leukemia That Allowed Oral Anticoagulant Treatment for Severe Cardiomyopathy

Division of Hematology, Principe de Asturias University Hospital, Madrid, Spain

Correspondence should be addressed to Juárez Salcedo Luis Miguel; moc.liamg@zeraujsiul.rd

Received 4 January 2017; Revised 12 February 2017; Accepted 19 March 2017; Published 2 April 2017

Academic Editor: Massimo Gentile

Copyright © 2017 Juárez Salcedo Luis Miguel and Gil-Fernández Juan José. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Duek, L. Shvidel, A. Braester, and A. Berrebi, “Clinical and Immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders,” Israel Medical Association Journal, vol. 8, no. 12, pp. 828–831, 2006. View at Google Scholar · View at Scopus
  2. K. Hodgson, G. Ferrer, E. Montserrat, and C. Moreno, “Chronic lymphocytic leukemia and autoimmunity: a systematic review,” Haematologica, vol. 96, no. 5, pp. 752–761, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Moreno, K. Hodgson, G. Ferrer et al., “Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance,” Blood, vol. 116, no. 23, pp. 4771–4776, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Visco, M. Ruggeri, M. L. Evangelista et al., “Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia,” Blood, vol. 111, no. 3, pp. 1110–1116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. K. A. Rogers and J. A. Woyach, “Secondary autoimmune cytopenias in chronic lymphocytic leukemia,” Seminars in Oncology, vol. 43, no. 2, pp. 300–310, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Stasi, M. L. Evangelista, and S. Amadori, “Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura,” Drugs, vol. 68, no. 7, pp. 901–912, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. D'Arena and N. Cascavilla, “Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia,” Leukemia and Lymphoma, vol. 52, no. 4, pp. 701–704, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Koehrer, M. J. Keating, and W. G. Wierda, “Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP,” Leukemia, vol. 24, no. 5, pp. 1096–1098, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. B. Bussel, D. J. Kuter, V. Pullarkat, R. M. Lyons, M. Guo, and J. L. Nichol, “Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP,” Blood, vol. 113, no. 10, pp. 2161–2171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Dearden, “Disease-specific complications of chronic lymphocytic leukemia,” Hematology. American Society of Hematology. Education Program, vol. 1, pp. 450–456, 2008. View at Google Scholar · View at Scopus
  11. F. R. Mauro, R. Foa, R. Cerretti et al., “Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features,” Blood, vol. 95, no. 9, pp. 2786–2792, 2000. View at Google Scholar · View at Scopus
  12. G. Borthakur, S. O'Brien, W. G. Wierda et al., “Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab—incidence and predictors,” British Journal of Haematology, vol. 136, no. 6, pp. 800–805, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Jolliffe and K. Romeril, “Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia,” Internal Medicine Journal, vol. 44, no. 7, pp. 697–699, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Rodeghiero, R. Stasi, T. Gernsheimer et al., “Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group,” Blood, vol. 113, no. 11, pp. 2386–2393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Provan, R. Stasi, A. C. Newland et al., “International consensus report on the investigation and management of primary immune thrombocytopenia,” Blood, vol. 115, no. 2, pp. 168–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Sinisalo, M. Sankelo, and M. Itälä-Remes, “Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia,” Leukemia and Lymphoma, vol. 52, no. 4, pp. 724–725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Tadmor and A. Polliack, “Expanding the use of thrombopoietin mimetic drugs: what about chronic lymphocytic leukemia?” Leukemia and Lymphoma, vol. 52, no. 4, pp. 558–559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. P. Garnock-Jones and S. J. Keam, “Eltrombopag,” Drugs, vol. 69, no. 5, pp. 567–576, 2009. View at Publisher · View at Google Scholar · View at Scopus